These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1925447)

  • 1. [Antiretroviral therapy in Switzerland 1991].
    Hirschel B; Vanhems P
    Schweiz Med Wochenschr; 1991 Aug; 121(34):1187-93. PubMed ID: 1925447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antiviral drugs--1988].
    Hirschel B
    Schweiz Med Wochenschr; 1988 Dec; 118(49):1830-7. PubMed ID: 2851167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zidovudine for the treatment of HIV infection.
    Pepe R; Molavi A
    Am Fam Physician; 1990 Aug; 42(2):437-43. PubMed ID: 2200250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zidovudine (Retrovir) update.
    Rachlis AR
    CMAJ; 1990 Dec; 143(11):1177-85. PubMed ID: 2224694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
    Whitfield RM; Bechtel LM; Starich GH
    Alcohol Clin Exp Res; 1997 Feb; 21(1):122-7. PubMed ID: 9046384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What we know about anti-HIV drugs.
    Treat Rev; 1995 May; (no 18):3-4. PubMed ID: 11362592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-retroviral therapy of HIV-infection. With preliminary results of the Swiss postmarketing surveillance of zidovudine].
    Jost J; Lüthy R
    Schweiz Med Wochenschr; 1991 Apr; 121(16):555-65. PubMed ID: 1904164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Once-daily administration of didanosine in combination with anti-retroviral zidovudine in previously untreated patients].
    Reynes J; Montes B; Delmas B; Vendrell JP; Janbon F; Segondy M
    Pathol Biol (Paris); 1997 May; 45(5):441-4. PubMed ID: 9296101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine.
    Yerly S; Kaiser L; Baumberger C; Hirschel B; Perrin LH
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):358-64. PubMed ID: 7882100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study.
    Stambuk D; Youle M; Hawkins D; Farthing C; Shanson D; Farmer R; Lawrence A; Gazzard B
    Q J Med; 1989 Feb; 70(262):161-74. PubMed ID: 2512592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current perspectives on antiretroviral therapy.
    Fletcher CV
    Pharmacotherapy; 1993; 13(6):627-33. PubMed ID: 7508101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of didanosine in the management of HIV-1 infection.
    Gazzard BG; Moyle GJ
    Antivir Ther; 1997 Jul; 2(3):135-47. PubMed ID: 11322269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
    Gatell JM; González-Lahoz J; Clotet B; Antunes F; Kasparova L; Gil-Aguado A; Saballs P; Santamaria JM; Podzamczer D; Miro JM; Jou A; Verdejo J; Doroana M; Thomis J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AIDS: Part II.
    Kessler HA; Bick JA; Pottage JC; Benson CA
    Dis Mon; 1992 Oct; 38(10):691-764. PubMed ID: 1396036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.